Loading
BGB-43395 is an experimental small-molecule drug from BeOne Medicines in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
BGB-43395 is a small-molecule drug developed by BeOne Medicines. The sponsor describes its target as CDK4, which OnCo does not yet have a target page for. The sponsor states: A CDK4-selective inhibitor designed to spare CDK6, intended to drive down cancer cell growth signalling while reducing the blood-cell toxicities associated with CDK6 inhibition. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07492641 (BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease), in HR-positive / HER2-negative breast cancer. The largest, NCT07492641, plans to enrol 1056 participants with primary completion expected 2029-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A CDK4-selective inhibitor designed to spare CDK6, intended to drive down cancer cell growth signalling while reducing the blood-cell toxicities associated with CDK6 inhibition.
1.BGB-43395 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BGB-43395" OR ABSTRACT:"BGB-43395") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BGB-43395, not a curated reading list.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.